TheraRadar
← Back
Data updated: Jun 28, 2026

ARCUTIS

Pharma
DermatologyImmunology Execution: Excellent

ARCUTIS is a pharmaceutical company focused on Dermatology, Immunology. Key products include ZORYVE.

2022
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

ARCUTIS at a Glance

  • Strong track record with 94% execution quality across 25 trials
  • Fast trial execution (11 months median completion)

ARCUTIS's Key Drugs

ARCUTIS's core commercial portfolio centers on ZORYVE, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.

ZORYVE
Immunology

Plaque Psoriasis

PDE4 Approved 2022

ARCUTIS's Recent FDA Approvals

New NDA/BLA approvals for ARCUTIS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ARCUTIS's Therapeutic Areas

ARCUTIS's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 51%
1 drugs Phase 3: 5 Phase 2: 4 Phase 1: 3
Immunology 49%
1 drugs Phase 3: 4 Phase 2: 5 Phase 1: 3

ARCUTIS's Top Competitors

ARCUTIS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Immunology, Dermatology
Eli Lilly big-pharma
Immunology, Dermatology
BAUSCH specialty
Dermatology, Immunology
BAUSCH AND LOMB INC other
Dermatology, Immunology
PHARMACIA AND UPJOHN big-pharma
Dermatology, Immunology

ARCUTIS Pipeline Snapshot

ARCUTIS has 24 active clinical programs from ClinicalTrials.gov — 9 Phase 3, 9 Phase 2 and 6 Phase 1.

9
Phase 3
9
Phase 2
6
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ZORYVE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 9/9 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges